fbpx

molecules of the month

BMS-986260

selective TGFβR1 kinase inhibitor

completed oral CV studies in higher species

from data mining of internal matter and opt.

ACS Med. Chem. Lett. 11, 172-178

Bristol-Myers Squibb, Princeton, NJ

BMS-986260
1 min read

BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: